展望未来，美国达乐公司预计，2025财年每股收益在6.30美元至6.50美元之间，高于市场预期的6.14美 元，而此前指引为5.80美元至6.30美元；预计其同店销售额将同比增长2.5%至2.7%，而此前指引为2.1% 至2.6%；预计净销售额将增长4.7%至4.9%，而此前指引为4.3%至4.8%。 周四，美国达乐公司(DG.US)涨8%，报118.73美元。该公司三季度盈利超出预期，并上调了年度利润预 期。根据LSEG收集的数据，Q3每股盈利1.28美元，同比增长44%，而分析师的预期为0.95美元。Q3净 销售额为106.5亿美元，略高于106.4亿美元的预期值。 ...

Group 1 - The core viewpoint of the report is that Zhongyou Securities has given WuXi AppTec (603259.SH, latest price: 91.13 yuan) a buy rating due to its strong business performance [2] - The Chemistry business revenue continues to grow rapidly, while the Testing business revenue has stabilized [2] - The company has maintained a rapid growth in its order backlog and has raised its full-year revenue guidance [2]

Summary of Earnings Call Records Company Overview - The company discussed in the earnings call is CRL, which operates in the biopharmaceutical industry, particularly focusing on DSA (Drug Substance and Analytical) services and other related segments. Key Financial Highlights - 1Q25 overall revenue was $984 million, a year-over-year decline of 2.7%, with organic revenue (excluding currency effects, acquisitions, and divestitures) down by 1.8%, which was better than the previously expected single-digit decline [1][2] - Non-GAAP Operating Margin (OM) was 19.1%, an increase of 0.6 percentage points year-over-year [1] - Non-GAAP EPS was $2.34, reflecting a year-over-year increase of 3.1% [1] DSA Segment Performance - DSA segment revenue for 1Q25 was $590 million, with organic revenue down 1.4% year-over-year [2] - New orders in the DSA segment reached $620 million in 1Q25, a quarter-over-quarter increase of 20%, with netb2b exceeding 1 for the first time since 2022H2, indicating a recovery in order backlog [2] - The company raised its full-year guidance for the DSA segment, now expecting a low single-digit decline in revenue, improved from a previously anticipated mid-high single-digit decline [2] Industry Insights - Approximately 25% of the company's revenue comes from large molecules, with around 10% from monoclonal antibodies and 15% from other large molecules. The recent FDA regulations aimed at reducing animal testing are expected to have a minimal short-term impact on performance [1] - The company remains cautious regarding the potential impacts of budget cuts from NIH/FDA, Q1 financing conditions, and tariffs [2] Other Business Segments - RMS (Research Model Services) revenue for 1Q25 was $210 million, with organic revenue down 2.5%, aligning with previous expectations. Growth in small animal model sales, primarily due to price increases, was a key driver [2] - Manufacturing segment revenue for 1Q25 was $180 million, with organic revenue down 2.2% [2] - The company anticipates a full-year organic revenue decline of 4.5% to 2.5%, revised from a previous forecast of 5.5% to 3.5% [3] Conclusion - The overall sentiment in the industry remains cautious, but there are no signs of further deterioration. The company is adjusting its expectations based on current market conditions and performance trends [2][3]